【摘要】：目的探討抗纖軟肝膠囊對大鼠肝纖維化肝星狀細(xì)胞(HSC)活化及凋亡的影響。方法將32只清潔級SD大鼠采用隨機(jī)數(shù)字表法分為正常對照組和肝纖維化建模組各16只。建模組大鼠皮下注射四氯化碳(CCl_4)誘導(dǎo)大鼠肝纖維化,正常對照組以同樣方法注射等量植物油,隨后將正常對照組隨機(jī)分為正常組8只,藥物組8只,建模組隨機(jī)分為模型組8只,治療組8只。藥物組、治療組均給予抗纖軟肝膠囊治療,其他組同期灌服相當(dāng)量的生理鹽水。應(yīng)用蘇木素-伊紅(HE)染色和Masson染色觀察各組肝臟病理組織學(xué)改變;檢測各組大鼠血清丙氨酸氨基轉(zhuǎn)移酶(ALT)、天冬氨酸氨基轉(zhuǎn)移酶(AST)、白蛋白(ALB)、透明質(zhì)酸(HA)、層黏連蛋白(LN)、Ⅳ-C型膠原(Ⅳ-C)及Ⅲ型前膠原(PC-Ⅲ)水平;RT-PCR法或流式細(xì)胞術(shù)檢測各組血清體外對HSC-T6細(xì)胞中α平滑肌動蛋白(α-SMA)和轉(zhuǎn)化生長因子(TGF)-β1 mRNA表達(dá)以及細(xì)胞凋亡水平的影響。結(jié)果與模型組大鼠比較,治療組大鼠肝臟的肝纖維化程度減輕;治療組血清ALT、AST、HA、LN、IV-C、PC-Ⅲ水平明顯低于模型組,而ALB水平明顯高于模型組(均P0.05);體外實驗發(fā)現(xiàn)藥物組及治療組α-SMA和TGF-β1 mRNA的表達(dá)水平顯著低于正常組及模型組(均P0.05)。流式細(xì)胞術(shù)檢測結(jié)果顯示,藥物組及治療組HSC-T6的凋亡水平顯著高于正常組及模型組(均P0.05)。結(jié)論抗纖軟肝膠囊通過參與調(diào)控HSC的活化及凋亡,可發(fā)揮對肝纖維化大鼠的治療作用。
[Abstract]:Objective to investigate the effect of Kangxian Ruanggan capsule on (HSC) activation and apoptosis of hepatic stellate cells in rats with hepatic fibrosis. Methods 32 clean grade SD rats were randomly divided into normal control group and hepatic fibrosis model group. The model group rats were subcutaneously injected with carbon tetrachloride (CCl_4) to induce hepatic fibrosis, and the normal control group was injected with the same amount of vegetable oil in the same way. Then the normal control group was randomly divided into normal group (n = 8) and drug group (n = 8). The model group was randomly divided into model group (n = 8) and treatment group (n = 8). The drug group and the treatment group were treated with Kangxian Ruanggan capsule, while the other groups were given a considerable amount of normal saline at the same time. The histopathological changes of liver were observed by hematoxylin eosin (HE) staining and Masson staining. Serum alanine aminotransferase (ALT),) aspartate aminotransferase (AST),) albumin (ALB), (HA), laminin type 鈪，

本文編號：2268121